Vaxcyte, Inc. PCVX Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five?
- Vaxcyte, Inc. (PCVX) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five of $1B in Q1 2026.
- How has Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five changed year-over-year?
- Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five decreased by 21.5% year-over-year, from $1.28B to $1B.